

Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development

NCT07033663

Status RECRUITING
Sponsor Fundació Sant Joan de Déu
Enrollment 90 participants

Key Eligibility Criteria

Inclusion (5)

- Pregnant women with immune-mediated inflammatory or oncologic diseases, categorized into:
- High-exposed group: monoclonal treatment throughout pregnancy.
- Low-exposed group: monoclonal treatment limited to the first/second trimester.
- Non-exposed group: No monoclonal exposure or treatment with non-placental-crossing biologics, serving as a control to distinguish immunological changes attributable to maternal disease.
- \-

Locations (3 total)

Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain
Hospital Clínic de Barcelona, Barcelona, Spain
Hospital Universitari Vall d'Hebrón, Barcelona, Spain